SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

1349

CNE1000000W4

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:49 2024-05-06 am EDT			5-day change	1st Jan Change
2.18 ^HKD	+1.40%		+0.46%	-14.51%

Apr. 29	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	MT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.(SHSE:688505) added to Shanghai Stock Exchange A Share Index

June 21, 2021 at 12:00 am EDT

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Added

Latest news about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	Apr. 22	MT
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	Mar. 31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	Mar. 28	CI
Fudan-Zhangjiang Bio's 2023 Profit Falls	Feb. 26	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	Jan. 04	MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	Jan. 03	MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	Dec. 27	MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	Dec. 18	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	Dec. 18	CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	Nov. 13	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	Nov. 13	CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	Nov. 08	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	Nov. 08	CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	23-10-31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23-10-23	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	23-10-20	CI
Fudan-Zhangjiang Bio Puchases Structured Deposit Products	23-10-12	MT
Fudan-Zhangjiang Bio Swings to Profit in H1	23-08-11	MT
Fudan-Zhangjiang Bio Enrolls First Patient in FZ-AD004 Clinical Trial	23-08-10	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors	23-08-09	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-02	CI
Fudan-Zhangjiang Bio to Swing to H1 Profit	23-07-18	MT

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

More charts

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.	-14.51%	849M
KYOWA KIRIN CO. LTD.	+12.55%	9.3B
SK BIOPHARMACEUTICALS CO., LTD.	-13.75%	5.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+41.51%	4.47B
YUHAN CORPORATION	+4.51%	3.96B
INDIVIOR PLC	+21.10%	2.44B
BETTA PHARMACEUTICALS CO., LTD.	-15.23%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-25.12%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+5.43%	1.69B

Specialty & Advanced Pharmaceuticals